
Karl Friedrichsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11005406/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Science Translational Medicine, 2016, 8, 338ra66.	12.4	560
2	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. JAMA Neurology, 2016, 73, 1070.	9.0	246
3	Partial volume correction in quantitative amyloid imaging. NeuroImage, 2015, 107, 55-64.	4.2	188
4	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	7.6	150
5	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. Neurolmage, 2017, 161, 171-178.	4.2	116
6	Neuropathologic assessment of participants in two multiâ€center longitudinal observational studies: The <scp>A</scp> lzheimer <scp>D</scp> isease <scp>N</scp> euroimaging <scp>I</scp> nitiative (<scp>ADNI</scp>) and the <scp>D</scp> ominantly <scp>I</scp> nherited <scp>A</scp> lzheimer <scp>N</scp> etwork (<scp>DIAN</scp>). Neuropathology, 2015, 35, 390-400.	1.2	68
7	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45
8	Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
9	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	2.4	14